Siegfried Holding AG operates in the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Siegfried Holding AG with three other
pharmaceutical manufacturers in Europe:
Swedish Orphan Biovitrum AB (publ)
sales of 6.51 billion Swedish Kronor [US$774.72 million]
(617.54 million Euro [US$764.28 million]
based in Italy
(637.49 million Euro [US$788.97 million]
Siegfried Holding AG reported sales of 750.47 million Swiss Francs (US$774.48 million)
December of 2017.
increase of 4.6%
versus 2016, when the company's sales were 717.73 million Swiss Francs.
This was the third consecutive year of growth at Siegfried Holding AG.
Sales of Drug Products saw an increase
6.3% in 2017, from
159.80 million Swiss Francs to 169.80 million Swiss Francs.